Stock comparison
Bio-Rad Laboratories
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 71B | UTHR |
| Benjamin Graham | 48D | 76B | UTHR |
| Philip Fisher | 30F | 76B | UTHR |
| Peter Lynch | 10F | 62C | UTHR |
| Joel Greenblatt | 42D | 46D | UTHR |
| Charlie Munger | 34F | 64C | UTHR |
| Terry Smith | 26F | 64C | UTHR |
Side-by-side metrics
| Metric | BIO | UTHR |
|---|---|---|
| Market cap | $7.78B | $24.13B |
| P/E (TTM) | 39.5x | 19.2x |
| EV/EBIT | 28.0x | 15.2x |
| ROIC (TTM) | 1.95% | 18.81% |
| Gross margin | 51.87% | 86.58% |
| Net margin | 6.52% | 40.61% |
| Revenue CAGR 5y | -3.04% | 17.22% |
| EPS CAGR 5y | -33.51% | 29.84% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
No clear edges - the other side wins or ties on every measured metric.
UTHR leads on
- EPS CAGR 5y29.84%vs -33.51%+189%
- Revenue CAGR 5y17.22%vs -3.04%+118%
- Debt / Equity-vs 0.2x+100%
- ROIC (TTM)18.81%vs 1.95%+90%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.